UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | --- | |---------------------------------------------------------------------------------------|----------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-----------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------ ...

39th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman JANUARY 14, 2021 © 2021 CytomX Therapeutics, Inc. Conditionally-Active Antibody Therapeutics for the treatment of cancer © 2020 CytomX Therapeutics, Inc. Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Stephanie Ascher - Investor Relations Sean McCarthy - President & Chief Executive Officer Amy Peterson - Chief Financial Officer Carlos Campoy - Senior Vice President & Chief Financial Officer Conference Call Participants Terence Flynn - Goldman Sachs Mara Goldstein - Mizuho Etzer Darout - Guggenheim Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------|----------------------------------------- ...

REIMAGINING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER Wedbush PacGrow Healthcare Conference AUGUST 12, 2020 © 2020 CytomX Therapeutics, Inc. 1 Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical a ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call August 6, 2020 5:30 PM ET Company Participants Christopher Keenan – Vice President of Investor Relations Sean McCarthy – President, Chief Executive Officer and Chairman Carlos Campoy – Senior Vice President and Chief Financial Officer Conference Call Participants Waleed – Barclays Etzer Darout – Guggenheim Securities Terence Flynn – Goldman Sachs Biren Amin – Jefferies Mara Goldstein – Mizuho Mohit Bansal – Citi Joe Catanzaro – Piper S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or other jurisdiction of incorporation or organiz ...

REIMAGINING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER Goldman Sachs 41st Annual Global Healthcare Conference JUNE 10, 2020 © 2020 CytomX Therapeutics, Inc. 1 Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products ...